Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Case-control study of ocular hypertension.

J M Seddon, B Schwartz, G Flowerdew

    Archives of Ophthalmology (Chicago, Ill. : 1960)
    |June 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

    Gynecologic oncology·2006
    Same author

    Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

    European journal of cancer (Oxford, England : 1990)·2006
    Same author

    How often should a port-A-cath be flushed?

    Cancer investigation·2005
    Same author

    An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

    Investigational new drugs·2005
    Same author

    HTS magnetometers for fetal magnetocardiography.

    Neurology & clinical neurophysiology : NCN·2005
    Same author

    Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2005

    Ocular hypertension risk factors include a family history of glaucoma, myopia, and high blood pressure. Absence of alcohol consumption and high income were also linked to higher ocular hypertension prevalence.

    Area of Science:

    • Ophthalmology
    • Public Health

    Background:

    • Ocular hypertension is a significant risk factor for glaucoma, a leading cause of irreversible blindness.
    • Identifying risk factors for ocular hypertension is crucial for early detection and intervention strategies.

    Purpose of the Study:

    • To investigate demographic, personal, environmental, and medical factors associated with ocular hypertension.
    • To determine independent predictors of ocular hypertension using statistical analysis.

    Main Methods:

    • Retrospective case-control study involving 100 ocular hypertensive and 100 ocular normotensive patients.
    • Data collection through patient interviews and medical chart reviews.
    • Multiple logistic regression analysis to identify significant risk factors.

    Related Experiment Videos

    Main Results:

    • Significant associations with ocular hypertension included: family history of glaucoma, myopic refractive error, absence of liquor intake, history of nonocular surgery, high income, and history of high blood pressure.
    • These factors were independently related to the presence of ocular hypertension.

    Conclusions:

    • Several modifiable and non-modifiable factors are associated with ocular hypertension.
    • Further research into these factors may inform targeted screening and prevention programs for glaucoma.